MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
María Luz Morales(Research Institute Hospital 12 de Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), María Linares(Universidad Complutense de Madrid), Inmaculada Rapado(Wellcome Sanger Institute), Nerea Castro(Hospital Universitario 12 De Octubre), Ivana Zagorac(Spanish National Cancer Research Centre), Gonzalo Goméz-López(Spanish National Cancer Research Centre), Alicia Arenas(Universidad de Sevilla), Alejandra Leivas(Spanish National Cancer Research Centre), Rosa Ayala(Hospital Universitario 12 De Octubre), Alba Rodríguez-García(Research Institute Hospital 12 de Octubre), Miguel Gallardo(Spanish National Cancer Research Centre), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre)
Cited by 32
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523